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Therapeutic strategies that target glycolysis and biosynthetic pathways in cancer cells are currently the main
focus of research in the field of cancermetabolism. In this issue ofCancer Cell, Hitosugi and colleagues show
that targeting PGAM1 could be a way of ‘‘killing two birds with one stone’’.The metabolism of cancer cells differs
from that of many normal cells and is
mostly characterized by higher rates of
glucosemetabolism under normal oxygen
levels. This trait enables cancer cells to
satisfy their demand for both energy and
biosynthetic building blocks required for
proliferation. For that reason, it is not
surprising that many glycolytic enzymes
are commonly overexpressed in tumors
(Tennant et al., 2009). Phosphoglycerate
mutase (PGAM1) catalyzes the conver-
sion of 3-phosphoglycerate (3PG) into 2-
phosphoglycerate (2PG) as part of the
glycolytic pathway using a phospho-histi-
dine residue at the enzyme’s catalytic
domain (His11) as a phosphate donor/
acceptor and 2,3-bisphosphoglycerate
as an intermediate metabolite (Fothergill-
Gilmore and Watson, 1989). In humans,
PGAM1 is widely expressed at levels
that vary among different tissues as well
as during differentiation and transforma-
tion. PGAM1 is overexpressed in several
types of cancer (Fothergill-Gilmore and
Watson, 1989; Ren et al., 2010). Because
PGAM1 expression is negatively regu-
lated by the tumor suppressor TP53, the
loss of the latter may cause increased
expression of PGAM1 in cancer. This
portrays PGAM1 as a potential thera-
peutic target, and indeed, pharmaco-
logical inhibition of PGAM1 reduced
proliferation of breast cancer cells (Evans
et al., 2005). Furthermore, in cancer cells
that overexpress the tightly-regulated iso-
form of pyruvate kinase PKM2, PGAM1
phosphorylation on His11, and hence
PGAM1’s activity, are induced by phos-
phoenolpyruvate, the substrate of pyru-
vate kinase (Vander Heiden et al., 2010).
The notion that metabolites can act as
signaling molecules in distant metabolic
pathways is gaining significant attentionand support (Figure 1A). Some of the
best known examples are the activation
of PKM2, which catalyzes the last step
of glycolysis, by fructose 1,6-bisphos-
phate (an upstream glycolytic inter-
mediate) and the inhibition of phospho-
fructokinase-1 (another key regulated
glycolytic enzyme) by phosphoenolpyr-
uvate, citrate, and ATP (Ashizawa et al.,
1991; Evans et al., 1981). These regula-
tory loops ensure that glycolytic interme-
diates are optimally utilized and chan-
neled into the appropriate metabolic
pathway to balance energetic and ana-
bolic demands. Recently, the amino acid
serine was demonstrated to bind and
directly activate PKM2 in order to control
the bifurcation point from glycolysis to
serine biosynthesis (Chaneton et al.,
2012). In line with this concept, this issue
of Cancer Cell features the work by Hito-
sugi et al. (2012), which demonstrates
that, in addition to their involvement in
glycolysis, both the substrate and product
of PGAM1 (3PG and 2PG, respectively)
modulate two other biosynthetic path-
ways derived from glycolysis: the oxida-
tive branch of the pentose phosphate
pathway (PPP) and the serine biosyn-
thesis pathway (Figure 1A).
Hitosugi et al. (2012) studied the
prospective therapeutic approach of
PGAM1 inhibition in cancer cells and the
associated metabolic consequences.
Silencing the expression of PGAM1 with
short-hairpin RNA caused an increase in
the intracellular levels of 3PG and a
decrease in 2PG levels, which is associ-
ated with a block in the glycolytic
flow. Surprisingly, the downregulation of
PGAM1 levels also inhibited the entry of
glucose 6-phosphate into the oxidative
PPP, a process which supports de novo
nucleotide biosynthesis. Hitosugi et al.Cancer Cell 22, N(2012) demonstrated that the increase in
3PG directly causes the inactivation of
the PPP enzyme 6-phosphogluconate
dehydrogenase (6PGD) by competing
with its substrate 6-phosphogluconate.
What’s more, the decrease in 2PG
levels upon PGAM1 downregulation was
accompanied by a reduction in phos-
phoglycerate dehydrogenase (PHGDH)
activity, which utilizes 3PG as a substrate
and carries out the first regulated step in
the serine biosynthesis pathway (Fig-
ure 1B). Interestingly, the cell permeable
analog of 2PG (methyl-2-PG) rescued
PGAM1-silenced cells by increasing the
flux of 3PG into the serine biosynthesis
pathway through PHGDH and, with
that, alleviated the inhibition of the PPP
by 3PG while also rescuing glycolysis.
Furthermore, a screen for small molecule
inhibitors of PGAM1 identified an allo-
steric inhibitor that affected cell metabo-
lism and growth of xenografted tumors
in vivo in a manner similar to PGAM1
silencing. These observations strengthen
the concept that targeting PGAM1
pharmacologically may be beneficial for
cancer therapy not only by reducing an
important energy source of cancer cells,
but also by preventing anabolic pro-
cesses required for cell growth and
proliferation.
The work by Hitosugi et al. (2012) not
only provides new insights into the
complex mechanism of metabolic regula-
tion (by identifying 2PG and 3PG as
signaling molecules that regulate biosyn-
thetic pathways), but also emphasizes
the potential effectiveness of exploiting
such complexity, which allows for the
targeting of both energetic and anabolic
processes with a single drug. However,
one of the main challenges in targeting
cancer metabolism is the robustnessovember 13, 2012 ª2012 Elsevier Inc. 565
Figure 1. The Dual Catabolic and Anabolic Roles of PGAM1 that Make It a Useful Target for
Cancer Treatment
(A) Glycolysis and biosynthetic processes that ‘‘branch’’ from glucose metabolism are required to support
growth and proliferation of cells. These processes must be tightly controlled and adjusted to meet cellular
needs. Intricate regulatory loop signals exist to enable such control. These include phosphofructokinase-1
(PFK1) inhibition by phosphoenolpyruvate (PEP) and the activation of pyruvate kinase (PK) M2 isoform
(PKM2) (the predominant isoform expressed in proliferating cells) by fructose 1,6-bisphosphate
(F1,6BP) and serine. PGAM1 is overexpressed in many cancer cells supporting energetic demands by
enabling increased glycolytic flux. At the same time, its product 2-phosphoglycerate (2PG) stimulates
phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first and rate-limiting step in the serine
biosynthesis pathway (purple rectangle).
(B) Upon inhibition of PGAM1, an increase in 3-phosphoglycerate (3PG) and a decrease in 2PG occur. This
leads to a decrease in glycolytic flow and energy production by PK as well as the tricarboxylic acid (TCA)
cycle in the mitochondria. In addition, the reduction in 2PG due to PGAM1 inhibition prevents the chan-
neling of 3PG into the serine biosynthetic pathway, leading to further accumulation of 3PG. Accumulated
3PG, in turn, inhibits 6-phosphogluconate dehydrogenase (6PGD) in the pentose phosphate pathway
(brown rectangle) and ribosome 5-phosphate (R5P) production. In effect, the inhibition of PGAM1, a glyco-
lytic enzyme, not only limits glycolysis, but also two important anabolic processes required for cell prolif-
eration.
Green or red dotted lines indicate direct positive or negative regulatory effects and green or red ovals
represent active or inactive enzymes, respectively. Black or gray arrows represent active or inhibited reac-
tions, respectively.
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Previewsand plasticity of metabolic networks that
allow cancer cells to adapt and overcome
impediments. In addition, a consideration
for long- and short-term toxicity to meta-
bolically active normal tissues must be
taken into account when a core glucose
metabolic pathway is being targeted.
Encouragingly, the in vivo work reported
by Hitosugi et al. (2012) demonstrated
a good therapeutic index for such a
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